Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 321

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 16G
Chunk 321
---
ITEM 16G. CORPORATE
GOVERNANCE

The Nasdaq Rules permit listed companies that are foreign private
issuers, such as us, to follow home country practice in lieu of the corporate governance provisions specified by the Nasdaq Rules with
limited exceptions.

In accordance with Israeli law and practice and subject to the
exemption set forth in Rule 5615 of the Nasdaq Rules, we have elected to follow the provisions of the Companies Law, rather than the Nasdaq
Rules, with respect to the following requirements:

  Distribution of periodic reports to shareholders.                                                                                                 

  Quorum. While the Nasdaq Rules require that                                                                                                    

107

  Nomination of Directors. We follow Israeli                                                                                                      
  corporate governance practices instead of the requirements of the Nasdaq Rules with regard to the nomination committee and director nomination  
  procedures. Israeli law and practice does not require director nominations to be made by a nominating committee of our board of                 
  directors consisting solely of independent directors, as required under the Nasdaq Rules. In accordance with Israeli law and practice,          
  directors are recommended by our board of directors for election by our shareholders (other than directors elected by our board of directors    
  to fill a vacancy), and certain of our shareholders may nominate candidates for election as directors by the general meeting of shareholders    
  in accordance with the Companies Law and our Articles of Association.                                                                           
 ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Compensation of Officers. We follow Israeli                                                                                                   

  Approval of Related Party Transactions.                                                                                                  
  We follow Israeli law and practice with respect to the approval of interested party acts and transactions, as set forth in sections 268  
  to 275 of the Companies Law, and the regulations promulgated thereunder, which generally require the approval of the audit committee,    
  the board of directors and, under certain circumstances (such as if the transaction is with a controlling shareholder or another party   
  in which the controlling shareholder has a personal interest) the shareholders, as may be applicable, for specified transactions. See    
  “ Item 6. C— Directors, Senior Management and Employees — Board Practices — Approval of Related Party Transactions                       
  under Israeli Law” for information regarding the approvals required with respect to approval of related party transactions pursuant      
  to the Companies Law.                                                                                                                    
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

  Shareholder